• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

NEW DELHI: Morepen Laboratories has filed 52 DMF (Drug Master File) across 10 European countries for six products.

The filings are for cholesterol-reducing drug Atorvastatin for both the amorphous and the crystalline forms, anti-asthmatic drug Desloratadine, anti-diabetic drug pioglitazone and antibacterial drugs Sultamicillin Tosylate and Sultamicillin Base.

Mr Sushil Suri, Chairman and Managing Director of Morepen Labs, said, "Looking at the emerging growth opportunities in the European generics market this is a move to increase our play in select high growth therapeutic categories. With these DMF filings we expect our European market share to go over 20 per cent over the next three years."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Glenmark's asthma drug gets nod for further trials

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line